Sep 15, 2023
Source:
Presented at the 18th German Allergy Congress
Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial (German) à link to Aygoren
Presentation 484.3 KB
Sep 15, 2023
Source:
Presented at the 18th German Allergy Congress
Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks (German) à link to Magerl
Presentation 395.9 KB
Sep 02, 2023
Source:
Presented at the HAEi Regional Conference EMEA, Munich, September 1-3
Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Presentation 1 MB
Sep 01, 2023
Source:
Presented at the HAEi Regional Conference EMEA, Munich, September 1-3
Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Poster 1 MB
Sep 01, 2023
Source:
Presented at the HAEi Regional Conference EMEA, Munich, September 1-3
Efficacy and safety of bradykinin B2 receptor antagonism with oral deucrictibant in prophylaxis of hereditary
Poster 319.2 KB
Jul 21, 2023
Treatment with oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule improves hereditary angioedema attack symptoms
Poster 1 MB
Jul 21, 2023
Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Poster 1.8 MB
Jun 11, 2023
Efficacy and Safety of Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe-1 Phase 2 Trial
Poster 700.6 KB
Jun 11, 2023
Treatment with Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 Improves Hereditary Angioedema Attack Symptoms
Poster 1.1 MB
May 06, 2023
Source:
Presented at the 13th C1-inhibitor Deficiency and Angioedema Workshop Budapest (Hungary), 4–7 May 2023
The EC85 Derived from the Oral Bradykinin B2 Receptor Antagonist Deucrictibant (PHA121) Against Bradykinin Effects in Healthy Volunteers Predicts the Onset and Duration of Its Clinical Effects in Hereditary Angioedema
Presentation 1.1 MB
May 06, 2023
Source:
Presented at the 13 th C1-inhibitor Deficiency and Angioedema Workshop Budapest (Hungary), 4–7 May 2023
Cardiovascular safety of the orally administered bradykinin B2 receptor antagonist, deucrictibant (PHA121, PHA-022121)
Poster 1.1 MB
May 06, 2023
Source:
Presented at the 13 th C1-inhibitor Deficiency and Angioedema Workshop Budapest (Hungary), 4–7 May 2023
Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate Release Capsule (PHVS416) in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe 1 Phase 2 Trial
Presentation 870.7 KB
May 06, 2023
Source:
Presented at the 13th C1-inhibitor Deficiency and Angioedema Workshop Budapest (Hungary), 4–7 May 2023
Efficacy of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) by attack location in the RAPIDe-1 phase 2 clinical trial for treatment of hereditary angioedema attacks
Poster 1.6 MB
May 05, 2023
Source:
Presented at the 13 th C1-inhibitor Deficiency and Angioedema Workshop Budapest (Hungary), 4–7 May 2023
Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Poster 850.4 KB
Mar 18, 2023
Source:
Presentated at 2023 HAEi Regional Conference APAC. Bangkok, Thailand – 17-19 March 2023
Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Presentation 920.2 KB
Feb 26, 2023
Source:
Presented at the 2023 American Academy of Allergy Asthma and Immunology Annual Meeting (AAAAI 2023) San Antonio, TX, USA; February 24–27, 2023
Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Poster 1.1 MB
Presentation 6.3 MB
Nov 13, 2022
Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist
Poster 937.4 KB
Nov 12, 2022
Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks
Poster 818.4 KB
Oct 07, 2022
Development of two novel oral formulations of a first in class bradykinin B2 receptor antagonist for on demand and prophylactic treatment of hereditary angioedema
Poster 920.1 KB
Sep 16, 2022
Source:
Presented at Bradykinin Symposium 2022. Berlin, Germany – 15-16 September 2022
Development of PHA121 for On-Demand and Prophylactic Treatment of HAE
Presentation 926.6 KB
Jun 07, 2022
Source:
Presented at Satellite Symposium Kinin 2022, June 7
Tailored drug development for patients living with HAE
Presentation 1.6 MB
Mar 22, 2022
Source:
Volume 105, April 2022, 108523
Pharmacological profile of PHA121 published in International Pharmacology
Jun 10, 2021
Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema
Poster 535.7 KB
Jun 04, 2021
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE
Presentation 4.9 MB
Presentation 38.7 MB
Feb 26, 2021
Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE
Poster 1.9 MB
Nov 13, 2020
Bradykinin Challenge Provides Surrogate Endpoints For Hereditary Angioedema Treatment
Poster 664.1 KB
Nov 13, 2020
PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans
Poster 746.5 KB
Jul 30, 2020
In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist
Publication 1.7 MB
Apr 09, 2020
PHA-022121, a First in Class Oral Bradykinin B2 Receptor Antagonist in Clinical Development: Proof of Concept Study in a Translational Monkey Bradykinin Challenge Model
Poster 931.5 KB